Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus low-dose dexamethasone in heavily pretreated refractory multiple myeloma
2016-003094-18Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor and dexamethasone in multiple myeloma (MM), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall response rate. Started Dec 2016; status: completed.
02
Drugs
selinexordexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-003094-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003094-18.